Achieving Glycemic Control in Type 2 Diabetes - A Quality Improvement Program for Primary Care

Title:

Achieving Glycemic Control in Type 2 Diabetes - A Quality Improvement Program for Primary Care

Topic: Endocrinology
Relevant Terms: Type 2 Diabetes; primary care; quality improvement
Primary Audience: Primary Care Clinicians
Launch Date: 06-Apr-18
Credits: AMA PRA Category 1 Credit
Expiration Date: 06-Apr-19
Curriculum Name: Improving the Quality of Care in Patients with Diabetes through a Simulated QI Experience

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Implement strategies for timely initiation and titration of insulin therapy in patients with type 2 diabetes
  2. Describe the clinical and pharmacokinetic/pharmacodynamic (PK/PD) differences between ultralong-acting and conventional basal insulins

    Faculty

    Carol Wysham, MD
    Clinical Professor of Medicine
    University of Washington School of Medicine
    Endocrinologist
    Rockwood Center for Diabetes and Endocrinology
    Spokane, WA 
    Davida F. Kruger, MSN, APN-BC, BC-ADM
    Certified Nurse Practitioner
    Henry Ford Health System, Division of Endocrinology
    Diabetes and Bone Disease
    Detroit, MI
    Felice Caldarella, MD, FACE, FACP, CDE
    Endocrinologist
    Center for Endocrine Health
    Hunterdon Medical Center
    Clinton, NJ
    LAUNCH DATE/EXPIRATION DATE
    This activity was launched on April 6, 2018 and will expire on April 6, 2019.
     
    TARGET AUDIENCE
    This activity has been designed to meet the educational needs of primary care clinicians, nurse practitioners (NPs), physician assistants (PAs) and other health care professionals involved in the care of patients with diabetes.

    SUPPORTER STATEMENT
    This activity was supported by an educational grant from Sanofi US.

    ACCREDITATION STATEMENT
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION
    Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    HOW TO CLAIM CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

    LEARNER ASSURANCE STATEMENT
    Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
     
    Name of Faculty Reported Financial Relationship
    Carol Wysham, MD
    Dr. Wysham has served on Speakers Bureaus for Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Insulet, Novo Nordisk and Sanofi.  She has served on Advisory Boards for Abbott, Astra Zeneca, Janssen, Novo Nordisk and Sanofi.  She has provided services for non-CME promotional purposes for Sanofi and Novo Nordisk.
    Davida F. Kruger, MSN, APN-BC, BC-ADM 
    Ms. Kruger has served on Advisory Boards for Abbott, Eli Lilly and Company, Janssen, Novo Nordisk, sanofi, Dexcom, Intarcia and Merck.       
    She has served on Speakers Bureaus for Abbott, Astra Zeneca, Boehringer Ingelhemi/Lilly, Eli Lilly and Company, Janssen, Novo Nordisk, Dexcom, Insulet and Valeritas.     
    Her institution has received grants/research support from Abbott, Astra Zeneca, Eli Lilly and Company, Novo Nordisk, Dexcom, and Lexicon. Ms. Kruger is a stockholder in Dexcom.
    Felice Caldarella, MD, FACE, FACP, CDE 
    Dr. Calderella discloses no relevant financial relationships with ACCME-defined commercial interests during the past 12 months.
     
     
    HORIZON PLANNER DISCLOSURES
     
    Horizon CME planners, non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME-defined commercial interests during the past 12 months.


    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above